The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...

GlobalData analyst Vasilis Roumpelakis notes that bispecifics could hold strong potential in the future, but manufacturing ...

Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

Fintel reports that on January 6, 2026, Barclays downgraded their outlook for Sanofi - Depositary Receipt (NasdaqGS:SNY) from ...

If you are wondering whether Sanofi shares around €82.29 offer good value today, you are not alone. This article is designed to help you frame that question clearly. The stock has had a mixed run, ...

Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

Five undervalued stocks including CleanSpark, Sanofi, Uber, Macy's and e.l.f. Beauty combine discounted valuations with ...

The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...

Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...